Little Green Pharma (ASX:LGP) chief executive Paul Long attests to official data showing the rapid uptake of medical cannabis in Australia – albeit with some informal anecdotal observations.
Read More
Perth-headquartered rock phosphate producer CI Resources has a unique claim to fame: it’s the only ASX-listed entity to operate on Christmas Island, the remote Australian territory in the Indian Ocean that is much closer to Jakarta than Canberra.
Read More
When it comes to cancer diagnostics, the ‘tried and trusted’ methods are often not the best ones, but merely the techniques clinicians are familiar with. For the ASX-listed INOVIQ (ASX:IIQ), the field is ripe for disruption and the company is wasting no time progressing its precision diagnostics based on two separate platform technologies – SubB2M and EXO-NET.
Read More
20 Jul 2023 – Altan Rio Minerals works on the simple ethos that ‘the best place to find a gold mine is next to a gold mine’.
Read More28 Jun 2023 – Identifying one of WA's most exciting lithium finds involved trawling through long-forgotten archives in the bowels of the state’s museum.
Read MoreLike its Australian Rules footballer namesake, Cazaly Resources has always flown high over the crowded pack of small-cap explorers since listing two decades ago.
Read MoreMining services provider Babylon Pump & Power has had a few setbacks over the last couple of years, but it is beginning to bear the fruits of management’s recapitalisation and refocusing effort.
Read MoreFor rare earths hopeful ABx Group, the ability to extract the coveted material economically is just as important as having a well-located deposit with the right size and grade in the first place.
Read MorePreviously focused on the Asian nation of Myanmar, Mallee Resources has refocused its efforts about 8000 kilometres south, in the mining-friendly jurisdiction of Tasmania.
Read MoreSigns of life are emerging in the global biotech sector after the longest and sharpest downturn in history that was so severe it left hundreds US companies trading below cash backing.
Read MoreWhen Michael Shelby and some colleagues formed Babylon Pump & Power in 2017, all he had was a good reputation in the sector spanning many decades. How things have changed.
Read MoreWhen you’re a small cap resources explorer on a tight budget, drawing on previous work on the same ground helps to shorten the odds of success – especially when they leave the riches behind.
Read MoreKalgoorlie Gold Mining sees no reason to stray beyond the storied WA gold region that shares its name. Tim Boreham takes a look into the recently listed miner.
Read MoreASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. Not, as Tim Boreham explains, the sort of ATM you might be thinking.
Read MoreMy Foodie Box sold its first meal kits in 2019 to 35 subscribers but now has an active subscriber base of more than 2000, with expectations of doubling this number by the end of 2022.
Read MoreAmong the various projects it currently has on the go, Tasmanian-based miner ABx Group is serving up rare earth treats for investors from its four Tasmanian super magnet metals prospects.
Read MoreCurrently a $10 million market cap tiddler, NickelX hopes to join the WA nickel big league with its acquired Cosmos South project, at the north-east end of the Fraser Range.
Read MoreKnown more as an Australian-focused medical cannabis minnow when it listed two years ago, Little Green Pharma now has access to more than half of the addressable EU market.
Read MoreThe sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising rates, dwindling liquidity and heightened geopolitical tensions.
Read MoreSometimes it’s the supposedly smaller things that can grind industry to a halt, such as the current shortage of the obscure diesel additive AdBlue. ABx Group may just have a solution.
Read MoreArdiden’s Pickle Lake Gold Project in the gold-rich province of Ontario is just down the road from mines operated by the likes of Evolution Mining, Newmont Mining and Barrick Gold.
Read MoreFor VIP Gloves, a pre-pandemic decision to expand its Malaysian production capacity has proved a positive strategic move capitalising on Malaysia’s dominant global glove manufacturing industry.
Read MoreIn his progression from student entrepreneur to founder of one of the world’s fastest growing online travel companies, 41-year-old Melburnian Adam Schwab has tackled plenty of business challenges.
Read MoreHumanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, leading to health problems.
Read MoreThe US Food and Drug Administration’s approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude to green-lighting novel drugs for difficult-to-treat illnesses.
Read MoreSpirit Technology Solutions has undergone an acquisition and organic sales-fuelled metamorphosis, selling an array of I.T. and telco add-on services to small to mid-sized businesses and not-for-profit clients.
Read MoreIt has been a rocky corporate journey for the ASX-listed Anteris Technologies, but with its revolutionary heart technology Anteris has the ticker to be the next Aussie medical device giant.
Read MoreTim Boreham has a look at Australian oil and gas developer Calima Energy (ASX: CE1) after its acquisition of Canadian producer Blackspur Oil and recent capital raising.
Read MoreLittle Green Pharma has become one of the few Australian cannabis companies with full approvals from both the TGA and the Office of Drug Control.
Read MoreTwo announcements from drug developer Antisense Therapeutics have raised hopes of an expedited path to market for its novel candidate to treat a genetic muscular disorder that affects only boys and is regressive, fatal, and poorly treated.
Read MoreKazia Therapeutics has been trialling its lead drug paxalisib (formerly GDC-0084) to treat the aggressive and complex disease. Paxalisib inhibits a signalling pathway called PI3K which is expressed in 85 per cent to 90 per cent of glioblastoma tumours. After years of quiet development, Kazia in August achieved two key milestones.
Read MoreWith Immutep’s largest and most advanced trial in breast cancer patients, AIPAC, the company is running it alone. Otherwise, its clinical activities revolve around partnerships with big pharmaceutical houses, which reduce the risk and cost of big-ticket drug development.
Read MoreAs a pioneer of advanced battery materials the ASX listed technology house Novonix is playing a key role in cracking the battery equivalent of Roger Bannister’s four-minute-mile in 1954.
Read MoreWhile local investors are unfamiliar with psychedelic therapy, this is likely to change given the burgeoning interest in North America, where no fewer than 20 companies are actively involved in the field.
Read MoreAssuming the lack of a bad debt apocalypse, the big banks certainly look cheap. But the smaller banks look even cheaper, which suggests there’s better value at the minnow end which is more oriented to mortgages than business lending.
Read MoreThe age-old notion of Australians betting on anything that crawls has been supported by the behaviour of sports punters during the virus lockdown that has stymied most professional sporting events.
Read MoreLittle Green Pharma was the first company to produce a home-grown medicinal cannabis product for patient use and it was also the first to export when it became legal to do so. Tim Boreham highlights why the company stands out as a genuine player above a canopy of chancers.
Read MoreThe New Criterion’s Tim Boreham highlights several mining services contractors, large and small, and their potential at this time.
Read MoreAs followers of uranium would know, there have been plenty of proclamations about an imminent recovery post Fukushima, but they have all turned out to be false dawns. With buyers and sellers trilling from the same song book, is this time different?
Read More
